文献速递角膜与眼表疾病

难治性单纯疱疹病毒性角膜炎的管理策略

Managing refractory herpes simplex keratitis.
PubMed 文献 · Br J Ophthalmol · 2026-09-23

本文综述了难治性单纯疱疹病毒性角膜炎(HSK)的管理策略。HSK由HSV-1引起,标准治疗包括抗病毒药物、皮质类固醇和眼表优化。难治性病例需重新评估依从性、药代动力学和病理生理,调整抗病毒剂量、使用保类固醇免疫调节剂,并控制眼表炎症。神经营养性角膜病变可用生长因子、自体血清、重组神经生长因子或巩膜镜。耐药株出现时可用三氟胸苷、膦甲酸或解旋酶-引物酶抑制剂。

要点

  • 难治性HSK需重新评估依从性、药物暴露和病理生理机制。
  • 神经营养性角膜病变可用生长因子、自体血清、重组神经生长因子或巩膜镜。
  • 耐药HSV-1可用三氟胸苷、膦甲酸或解旋酶-引物酶抑制剂如amenamevir。

核心结论

  • 针对难治性HSK的驱动因素采取新策略有助于快速缓解并降低复发风险,预防视力丧失。

研究设计与样本

  • 本文为综述,未报告具体检索范围。

主要发现

  • HSK由HSV-1引起,是发达国家感染性角膜盲的主要原因。
  • 难治性HSK定义为尽管适当治疗仍无临床改善。
  • 耐阿昔洛韦HSV-1株在免疫抑制或长期治疗患者中日益受关注。

关键数值与推荐

  • 标准管理包括抗病毒药物抑制病毒复制、皮质类固醇控制免疫性基质受累、眼表优化。
  • 难治性病例需调整抗病毒剂量、使用保类固醇免疫调节剂、严格控制眼表炎症。
  • 神经营养性角膜病变可能受益于生长因子疗法、自体血清、重组神经生长因子或巩膜镜。
  • 替代药物如三氟胸苷、膦甲酸或解旋酶-引物酶抑制剂(包括amenamevir)已显示临床疗效。

临床怎么用

  • 对难治性HSK应重新评估依从性、药代动力学暴露和潜在病理生理。
  • 根据病理生理组成调整抗病毒剂量并考虑保类固醇免疫调节剂。
  • 怀疑耐药时考虑替代药物如三氟胸苷、膦甲酸或解旋酶-引物酶抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Herpes simplex keratitis (HSK) caused by herpes simplex virus type 1 (HSV-1) is a major cause of infectious corneal blindness in developed countries. The disease reflects a variable combination of viral replication, immune-mediated inflammation and neurotrophic dysfunction, whose respective contributions determine both the clinical presentation and therapeutic strategy. Standard management relies on antiviral agents to suppress viral replication, corticosteroids to control immune stromal involvement and ocular surface optimisation to address chronic inflammation and neurotrophic impairment. Refractory forms, defined by a lack of clinical improvement despite appropriate treatment, require reassessment of adherence, pharmacokinetic exposureand underlying pathophysiology. In such cases, antiviral dose adjustment, the use of steroid-sparing immunomodulators and rigorous control of ocular surface inflammation are essential. Neurotrophic keratopathy may benefit from growth factor-based therapies, autologous serum, recombinant nerve growth factor or scleral lenses. The emergence of acyclovir-resistant HSV-1 strains, particularly in immunocompromised or long-term treated patients, represents an increasing concern. In these situations, alternative agents such as trifluridine, foscarnet or more recently, helicase-primase inhibitors, including amenamevir, have demonstrated clinical efficacy. The new strategies outlined here will all provide benefit in treating the drivers of refractory HSK, to quickly resolve and reduce risk of recurrence, providing new opportunities to prevent vision loss in refractory and antiviral-resistant cases.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Rousseau A, Boucher R, Haigh O, et al. Managing refractory herpes simplex keratitis. Br J Ophthalmol. 2026. PMID: 42778339. doi:10.1136/bjo-2025-329213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。